Literature DB >> 18713048

Pharmacokinetic and pharmacodynamic properties of meropenem.

David P Nicolau1.   

Abstract

Pharmacokinetic and pharmacodynamic profiles of antibiotics are important in determining effective dosing regimens. Although minimum inhibitory concentration (MIC) data reflect microbial susceptibility to an antibiotic, they do not provide dosing information. The integration of pharmacokinetic and microbiological data, however, can be used to design rational dosing strategies. Meropenem is a broad-spectrum beta-lactam antibiotic that penetrates most body fluids and tissues rapidly after intravenous administration. Meropenem undergoes primarily renal elimination; therefore, dosage adjustment is required for patients with renal impairment. Meropenem is indicated for the treatment of complicated skin and skin-structure infections, complicated intra-abdominal infections, and bacterial meningitis. Meropenem has time-dependent bactericidal activity; thus, the percentage of time that free-drug concentrations are higher than the MIC (%T>MIC) best characterizes the drug's pharmacodynamic profile (bactericidal target of approximately 40%T>MIC). Pharmacodynamic modeling can identify regimens with the greatest probability of attaining this target, and probabilities can be compared with clinical and microbiological responses in patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713048     DOI: 10.1086/590064

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  64 in total

1.  Does prolonged infusion allow lower daily dose of meropenem than bolus dosing?

Authors:  Eric Poulin; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

2.  In Vitro Stabilifighty Evaluation of Different Pharmaceutical Products Containing Meropenem.

Authors:  Cristina Tomasello; Anna Leggieri; Roberta Cavalli; Giovanni Di Perri; Antonio D'Avolio
Journal:  Hosp Pharm       Date:  2015-04-08

3.  Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.

Authors:  David C Griffith; Mojgan Sabet; Ziad Tarazi; Olga Lomovskaya; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

4.  In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.

Authors:  Maria Souli; Irene Galani; Stefanos Boukovalas; Michael George Gourgoulis; Zoi Chryssouli; Kyriaki Kanellakopoulou; Theofano Panagea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

5.  Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus.

Authors:  Sebastian G Wicha; Martin G Kees; Janin Kuss; Charlotte Kloft
Journal:  Pharm Res       Date:  2015-01-30       Impact factor: 4.200

6.  Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.

Authors:  Federico Pea; Pierluigi Viale; Piergiorgio Cojutti; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2012-10-08       Impact factor: 5.191

7.  Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?

Authors:  Valerio Del Bono; Daniele Roberto Giacobbe; Anna Marchese; Andrea Parisini; Carmen Fucile; Erika Coppo; Valeria Marini; Antonio Arena; Alexandre Molin; Antonietta Martelli; Angelo Gratarola; Claudio Viscoli; Paolo Pelosi; Francesca Mattioli
Journal:  Virulence       Date:  2016-07-18       Impact factor: 5.882

8.  New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.

Authors:  Janus A J Haagensen; Davide Verotta; Liusheng Huang; Alfred Spormann; Katherine Yang
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

9.  Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.

Authors:  Muhammad Usman; Otto R Frey; Georg Hempel
Journal:  Eur J Clin Pharmacol       Date:  2016-12-13       Impact factor: 2.953

10.  Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

Authors:  Sander P van Rijn; Marlanka A Zuur; Richard Anthony; Bob Wilffert; Richard van Altena; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.